OSLO, NORWAY - February 12, 2026: Microbiome DX company Genetic Analysis AS ("GA" or "the Company") announces that its important patent application CA2980637) has now been allowed for grant in Canada. The important patent entitled "METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS" covers the Company's unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. GA has an active patent strategy covering all major geographical markets and has previously announced approval in EU, China and other countries for this patent.
The subject matter of this family of patents relates to the sophisticated algorithms developed by Genetic Analysis that analyze and characterize gut microbiota in relation to healthy populations. The invention concerns the diagnosis, monitoring and/or characterization of diseases and conditions associated with perturbations in the microbiota of the gastrointestinal tract (GI). More specifically the invention provides means by which the state of the microbiota may be assessed and deviations from the normal state (normobiosis) may be determined in a manner which is straightforward to perform, reliable and robust and which is also flexible enough to be used with any technique for measuring levels of microorganisms in a Gl tract sample.
The patent has been allowed for grant by the Canadian Intellectual Property Office. The required grant fee has been paid and the patent is expected to be formally issued in Q1 2026. The patent family claims priority from 27 March 2015 and will be in force until 2036.
CEO Ronny Hermansen comments:
"We are delighted to announce that our patent "A method for determining gastrointestinal tract dysbiosis" has been allowed in Canada. The approval further strengthens our intellectual property portfolio and is an important step forward in GA's international expansion."